Impact of COVID-19 on healthcare programs in Zimbabwe: a mixed methods study
Nicholas Midzi(Ministry of Health and Child Welfare), Munyaradzi Dobbie(Ministry of Health and Child Welfare), Clara Haruzivishe(University of Zimbabwe), Virgininia Dube-Mawerewere(University of Zimbabwe), Mohd H. Abdul‐Aziz(The University of Queensland), Masceline Jenipher Mutsaka‐Makuvaza(Ministry of Health and Child Welfare), Senga Sembuche(Africa Centres for Disease Control and Prevention), Elizabeth Gonese(Africa Centres for Disease Control and Prevention), Tonny Muwonge(Infectious Diseases Institute), Isaac K. Phiri(University of Zambia), Tafadzwa Madanhire(University of Bristol), Rodgers R Ayebare(Infectious Diseases Institute), Cynthia Nombulelo Chaibva(National University of Science and Technology), Mosoka Papa Fallah(Africa Centres for Disease Control and Prevention), Calleta Gwatiringa(Ministry of Health and Child Welfare), Kudzai Elizabeth Mutsaka(Ministry of Health and Child Welfare), Patrice Chanda Kabwe(Africa Centres for Disease Control and Prevention), Raji Tajudeen(Africa Centres for Disease Control and Prevention), Carl Mateta(Ministry of Health and Child Welfare), S. Nakasendwa(Infectious Diseases Institute)
Cited by 1
Related Papers
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
|Intensive Care Medicine|2020|1.1k
Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort
|Journal of Antimicrobial Chemotherapy|2015|164
Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic Shock
|JAMA|2024|154
Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?
|International Journal of Antimicrobial Agents|2018|94
Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base
|Current Opinion in Infectious Diseases|2020|44